The use of melatonin as a sleep aid for children has become widespread across the globe, largely due to its reputation as a natural remedy for sleep difficulties. However, experts are raising alarms about the rapid increase in its use, which appears to be outpacing our understanding of its long-term safety and efficacy in pediatric populations. While there is notable evidence supporting melatonin's positive effects on sleep issues in children with neurodevelopmental disorders, such as autism and ADHD, we currently lack robust data regarding its impact on typically developing children. Moreover, concerns are being voiced regarding inconsistent dosages found in over-the-counter melatonin products, the potential for misuse without medical advice, and a troubling rise in accidental ingestions. These factors collectively underscore the urgent need for caution, enhanced regulation, and stronger, evidence-based guidelines regarding the administration of melatonin for childhood sleep challenges.
Sleep disturbances are increasingly prevalent among children and teenagers, posing risks to emotional regulation, cognitive development, and overall health. In their search for quick and effective solutions, many families are turning to melatonin supplements, drawn by their availability, child-friendly formulations, and the common perception that they are a safe, natural alternative to prescription medications. However, it’s crucial to remember that melatonin is a hormone that does more than influence sleep-wake cycles; it also plays a role in immune function, metabolism, and reproductive health. Unfortunately, research into melatonin usage in children is inconsistent, with most studies concentrating on short-term effects or specific clinical populations. This highlights an urgent need for comprehensive evaluations regarding the safety, effectiveness, and proper application of melatonin in young patients.
A recent narrative review published in the World Journal of Pediatrics on April 30, 2025, by a team of researchers from Boston Children's Hospital, investigates the increasing global trend of melatonin use in pediatric demographics. This valuable review compiles existing clinical evidence surrounding the effectiveness, safety, and practical usage patterns of melatonin among children and adolescents. It brings to light significant discrepancies between the widespread consumption of melatonin and the limited long-term data available, raising serious concerns about inappropriate usage, variability among products, and the lack of sufficient regulatory oversight for sleep aids designated for children.
The review indicates that the prevalence of melatonin use in children has soared over the last decade, particularly in countries where it is available as an over-the-counter supplement. Strong evidence exists that supports its short-term effectiveness for children diagnosed with neurodevelopmental conditions, such as autism spectrum disorder and attention-deficit hyperactivity disorder (ADHD). For these children, melatonin can help reduce the time it takes to fall asleep, prolong total sleep duration, and enhance the quality of life for caregivers.
In stark contrast, the evidence surrounding melatonin use in typically developing children is sparse and inconsistent. Most randomized controlled trials conducted in this population have been short-term and focused primarily on older children or adolescents, making it challenging to draw conclusions about its safety and effectiveness for younger children, where melatonin use is becoming increasingly common. Alarmingly, there is a significant lack of long-term safety data, leaving many questions unanswered regarding potential impacts on puberty, immune health, metabolic processes, and neurological development.
The review emphasizes concerning safety issues outside clinical settings. Analyses of commercial melatonin products reveal significant disparities between the labeled dosages and the actual amount of melatonin contained, with some items containing several times the declared dose or even unexpected compounds like serotonin. Additionally, pediatric poison control centers report a dramatic increase in accidental melatonin ingestions, especially among younger children, often linked to gummy formulations and improper storage practices. These alarming findings suggest that the real-world risks associated with melatonin may be significantly underestimated.
This review concludes that melatonin should not be perceived as a harmless solution for addressing sleep problems in children. While it may play a beneficial role in carefully selected cases—especially under medical supervision—it should never serve as a substitute for comprehensive sleep assessments or behavioral interventions. The authors stress that clinicians and caregivers should regard melatonin as a biologically active hormone rather than a benign dietary supplement. Without clearer evidence supporting its use and stricter regulations governing its distribution, routine or unsupervised melatonin use could expose children to unnecessary risks and divert attention from established, non-pharmacological strategies for promoting healthy sleep.
These insights carry significant implications for pediatric healthcare, public health policy, and caregiver education. Behavioral sleep interventions—such as establishing consistent bedtime routines, limiting screen time, and setting realistic expectations based on age—should remain the primary approach to treating childhood insomnia. When melatonin is deemed necessary, it is advisable to use the lowest effective dose for the shortest duration and always under medical supervision. The review also calls for improved regulation of pediatric melatonin products, clearer labeling standards, and long-term clinical studies. Together, these initiatives could help ensure that children receive safe, effective, and evidence-based support for their sleep needs.
